临床药师参与1例经皮冠状动脉介入术后个体化抗血小板治疗实践

刘俊,朱艳虹,储洁琼,徐文科,汪魏平,栾家杰

中国药学杂志 ›› 2015, Vol. 50 ›› Issue (22) : 2004-2007.

PDF(652 KB)
PDF(652 KB)
中国药学杂志 ›› 2015, Vol. 50 ›› Issue (22) : 2004-2007. DOI: 10.11669/cpj.2015.22.017
药物与临床

临床药师参与1例经皮冠状动脉介入术后个体化抗血小板治疗实践

  • 刘俊,朱艳虹,储洁琼,徐文科,汪魏平,栾家杰*
作者信息 +

Individualized Antiplatelet Therapy on One Patient with Stent Thrombosis after Percutaneous Coronary Intervention by Clinical Pharmacist

  • LIU Jun, ZHU Yan-hong, CHU Jie-qiong, XU Wen-ke, WANG Wei-ping, LUAN Jia-jie*
Author information +
文章历史 +

摘要

目的 探讨临床药师在经皮冠状动脉介入术后个体化抗血小板治疗中的作用。方法 回顾临床药师依据基因检测参与1例经皮冠状动脉介入术后支架内血栓形成的抗血小板治疗的案例。结果 临床药师依据基因检测分析经皮冠状动脉介入术后支架内血栓形成的原因,参与抗血小板治疗方案的调整,并对患者提供药学监护和用药教育,保证患者用药安全、有效。结论 临床药师依据基因检测参与临床治疗方案的制订和调整,为实施个体化用药提供依据,可作为临床药师药学服务的切入点。

Abstract

OBJECTIVE To evaluate the role of clinical pharmacist in individualized antiplatelet therapy in patients with percutaneous coronary intervention(PCI). METHODS To review clinical pharmacist participating antiplatelet therapy based on genotype detection for one patient with stent thrombosis after PCI. RESULTS Clinical pharmacist analyzed the causes of stent thrombosis after PCI by genotype detection,participated the adjustment of antiplatelet therapy and implemented pharmaceutical care and pharmaceutical education for the patient in order to ensure the safety and effectiveness of drug use. CONCLUSION Clinical pharmacist participates making and regulating the therapeutic regimen to provide some evidences for individualized medication,which could be the entry points to pharmaceutical care.

关键词

经皮冠状动脉介入术 / 支架内血栓形成 / 氯吡格雷抵抗 / 基因多态性 / 临床药师 / 个体化用药

Key words

percutaneous coronary intervention / stent thrombosis / clopidogrel resistance / gene polymorphism / clinical pharmacist / individualized medication

引用本文

导出引用
刘俊,朱艳虹,储洁琼,徐文科,汪魏平,栾家杰. 临床药师参与1例经皮冠状动脉介入术后个体化抗血小板治疗实践[J]. 中国药学杂志, 2015, 50(22): 2004-2007 https://doi.org/10.11669/cpj.2015.22.017
LIU Jun, ZHU Yan-hong, CHU Jie-qiong, XU Wen-ke, WANG Wei-ping, LUAN Jia-jie. Individualized Antiplatelet Therapy on One Patient with Stent Thrombosis after Percutaneous Coronary Intervention by Clinical Pharmacist[J]. Chinese Pharmaceutical Journal, 2015, 50(22): 2004-2007 https://doi.org/10.11669/cpj.2015.22.017
中图分类号: R969.3   

参考文献

[1] CHEN Z M,JIANG L X,CHEN Y P,et al. Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infaction:Randomised placebo-controlled trial[J]. Lancet,2005,366(9497):1607-1621.
[2] ZHANG Y,REN Y H,ZHOU C F,et al. Risk factor analysis of acute and sub-acute in-stent thrombosis in patients after percutaneous coronary intervention treatment[J]. Chin Circulation J(中国循环杂志),2013,28(1):17-20.
[3] AMUT E, UMER Y, JIA D M, et al.Practice and experience of developing drug administration in primary hospital[J]. Chin Pharm J(中国药学杂志), 2015,50(7): 650-652.
[4] LUO M, WU B, WU F B,et al .Impact of pharmacist-participated anticoagulation service on warfarin therapy management:A Systematic Review[J].Chin Pharm J(中国药学杂志), 2015,50(6): 554-558.
[5] FENG G X,LIANG Y,BAI Y,et al. Clopidogrel metabolism related gene polymorphisms in Chinese patients with acute coronary syndrome [J]. Chin J Cardiol(中华心血管病杂志),2012,40(11):908-913.
[6] COSTACH II,RUSU C,IVANOV I,et al. Clopidogrel resistance-risk factor in patients with acute coronary syndromes [J]. Rev Med Chir Soc Med Nat Iasi,2012,116(2):383-388.
[7] MEGA J L,CLOSE S L,HOCKETT R D,et al. Cytochrome P-450 polymorphisms and response to clopidogrel[J].N Engl J Med,2009,360:354-362.
[8] DAI Z L, CHEN H, WU X Y. Relationship between cytochrome P450 2C19*17 genotype distribution,platelet aggregation and bleeding risk in patients with blood stasis syndrome of coronary artery disease treated with clopidogrel[J]. JCIM,2012,10(6):647-654.
[9] MEGA J L,CLOSE S L,WIVIOTT S D,et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial:A pharmacogenetic analysis[J]. Lancet,2010,376(9749):1312-1319.
[10] OLIVERIRA S A,MANSUR A P,RIBEIRO C C,et al. PON1 M/L55 mutation protects high-risk patients against coronary artery disease[J]. Int J Cardiol,2004,94(1):73-77.
[11] SIMON T,VERSTUYFT C,MARY-KRAUSE M,et al. Genetic determinants of response to clopidogrel and cardiovascular events[J]. N Engl J Med,2009,360(4):363-375.
[12] CURRENT-OASIS 7 Investigators,MEHTA S R,BASSAND J P,et al. Dose comparisions of clopidogrel and asprin in acute coronary syndromes[J]. N Engl J Med,2010,363(10):930-942.
[13] ZHOU H,FENG X L,ZHANG H Y,et al. Triple versus dual antiplatelet therapy for coronary heart disease patients undergoing percutaneous coronary intervention:A Meta-analysis [J]. Exp Ther Med,2013,6(4):1034-1040.
[14] JAMES S,AKERBLOM A,CANNON C P,et al. Comparison of ticagrelor,the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndrome:Rational,design,and baseline characteristics of the platelet inhibition and patient outcome (PLATO) trial[J]. Am Heart J,2009,157(4):599-605.
[15] YE M,QIAO M,LIU C,et al.Smoking associated with aspirin and clopidogrel in patients with stable angina after percutaneous coronary intervention[J]. Chin J Rehabil Theory Pract(中国康复理论与实践),2010,16(11):1057-1059.

基金

皖南医学院中青年科研基金自然科学类资助项目(WK2014F20,WK2014F40)
PDF(652 KB)

Accesses

Citation

Detail

段落导航
相关文章

/